Pediatric Respiratory Medicine Department, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 611731, China.
Can Respir J. 2020 Nov 4;2020:7430936. doi: 10.1155/2020/7430936. eCollection 2020.
To evaluate the efficiency of sublingual immunotherapy with Dermatophagoides Farinae Drops in children with single and multiple respiratory allergic diseases.
Seventy-one children with allergic respiratory diseases who had been treated with Dermatophagoides Farinae Drops for one year or more were divided into a single allergic group (12 cases) and multiple allergic group (59 cases). The rhinitis score, daytime and night symptom score of asthma, VAS score, drug score, pulmonary function, and FeNO level before and after treatment were evaluated and compared between the two groups.
The rhinitis score, night symptom score, VAS score, and drug score in the single allergic group after treatment were significantly lower than those before treatment ( < 0.05), but there was no significant difference in the daytime symptom score before and after treatment ( > 0.05). The rhinitis score, VAS score, and drug score in the multiple allergic group after treatment were significantly lower than those before treatment ( < 0.05), but there was no significant difference in the scores of daytime symptoms and nighttime symptoms before and after treatment ( > 0.05). In both the single allergic group and multiple allergic group, the pulmonary function indexes of the patients were significantly improved after treatment, and the FeNO after treatment was significantly lower than that before treatment ( < 0.05). There was no significant difference in scores, pulmonary function, and FeNO between the two groups ( > 0.05).
Sublingual specific immunotherapy is effective in treating multiple and single allergic respiratory diseases in children.
评价舌下含服粉尘螨滴剂治疗儿童单一和多种呼吸道过敏性疾病的疗效。
71 例接受粉尘螨滴剂治疗 1 年以上的过敏性呼吸道疾病患儿分为单一过敏组(12 例)和多种过敏组(59 例)。评估并比较两组治疗前后的鼻炎评分、哮喘日间和夜间症状评分、VAS 评分、药物评分、肺功能和 FeNO 水平。
治疗后单一过敏组的鼻炎评分、夜间症状评分、VAS 评分和药物评分明显低于治疗前(<0.05),但日间症状评分治疗前后无明显差异(>0.05)。治疗后多种过敏组的鼻炎评分、VAS 评分和药物评分明显低于治疗前(<0.05),但日间和夜间症状评分治疗前后无明显差异(>0.05)。在单一过敏组和多种过敏组中,患者的肺功能指标治疗后均明显改善,治疗后 FeNO 明显低于治疗前(<0.05)。两组间评分、肺功能和 FeNO 无显著差异(>0.05)。
舌下特异性免疫疗法对治疗儿童多种和单一过敏性呼吸道疾病有效。